



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-0002

August 13, 2014

AMUSA  
Mr. Alex Ferri  
VP/GM of Operations  
5209 Linbar Dr, Suite 640  
Nashville, TN 37211

Re: K133685  
Trade/Device Name: 0.9% Sodium Chloride Flush Syringe  
Regulation Number: 21 CFR 880.5200  
Regulation Name: Device, Flush, Vascular Access  
Regulatory Class: II  
Product Code: NGT  
Dated: July 11, 2014  
Received: July 15, 2014

Dear Mr. Ferri:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Mary S. Runner -  
S 

Erin I. Keith, M.S.  
Director  
Division of Anesthesiology, General Hospital,  
Respiratory, Infection Control and  
Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Indications for Use

## Indications for Use Statement

510(k) Number (if known): K133685

Device Name: 0.9% Sodium Chloride Flush Syringe

Indications for Use:

"0.9% Sodium Chloride Flush Syringes are intended for use in flushing compatible intravenous administration sets and indwelling intravenous access devices. Use according to the recommendations of the manufacturer for the appropriate device".

Prescription Use      X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF  
NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

510(k) Summary



## 510(k) Summary

As required by 809.92(a) (2).

510 (k) PREMARKET NOTIFICATION NUMBER: K133685

### **Submitter and Owner of the 510(k)**

AMUSA  
5209 Linbar Dr., Suite 640  
Nashville, TN 37211  
Phone: 615-833-2633  
Fax: 615-425-2772

### **Official Correspondent**

Alex Ferri  
VP/GM of Operations  
AMUSA  
5209 Linbar Dr., Suite 640  
Nashville, TN 37211  
Phone: 615-833-2633  
Fax: 615-425-2772

**Date of Preparation: 5/15/14**

### **510(k) Application Number**

#### **Trade/Proprietary Name**

0.9% Sodium Chloride Flush Syringe

#### **Common Name/Usual Name**

Saline Flush Syringe

#### **Device Classification Name**

Device, Flush, Vascular Access

#### **Regulation Number**

880.5200

#### **Device Class**

Class II Device

#### **Classification Panel**

General Hospital

#### **Classification Product Code**

NGT

## **THE PREDICATE DEVICE DESCRIPTION:**

The Predicate Device, 510(k) Number: K120836 (AMUSA) consists of a non-sterile plastic 12 cc syringe filled with 3 mL, 5 mL, or 10 mL of 0.9% Sodium Chloride Flush Solution that is terminally sterilized. The predicate device is sterile on the outside and has a sterile fluid path. The Sterility Assurance Level (SAL) is  $10^{-6}$ . This is a single use device. The solution contains no preservatives, or antimicrobial agents. No plasticizers, additives, crosslink agents, reagents, or surfactants were used during the manufacture of the syringes. The syringe may be used on a sterile field if packaging is not damaged and aseptic technique is used.

### **Indications For Use:**

Intended use: 0.9% Sodium Chloride Flush Syringes are intended for use in flushing compatible intravenous administration sets and indwelling intravenous access devices. Use according to the recommendations of the manufacture for the appropriate device.

## **THE NEW DEVICE DESCRIPTION:**

The new device, the subject of this 510(k), consists of a 20 mL, non-sterile plastic syringe filled with 20 mL of 0.9% Sodium Chloride Flush Solution USP that is terminally sterilized. The new device is sterile on the outside and has a sterile fluid path. The Sterility Assurance Level (SAL) is  $10^{-6}$ . The syringe may be used on a sterile field if packaging is not damaged and aseptic technique is used. This is a single use device. The solution contains no preservatives, or antimicrobial agents. No plasticizers, additives, crosslink agents, reagents, colorants, inks, adhesives, surfactants, detergents, used during the manufacture of the syringes. The 20mL filled with 0.9% Sodium Chloride Flush Solution in a 20mL syringe is the only model which is subject to this 510(k). Other models previously cleared under 510K (K120836) consists of a non-sterile plastic 12 cc syringe filled with 3 mL, 5 mL, or 10 mL of 0.9% Sodium Chloride Flush Solution that is terminal sterilized.

### **Indications For Use:**

Intended use: 0.9% Sodium Chloride Flush Syringes are intended for use in flushing compatible intravenous administration sets and indwelling intravenous access devices. Use according to the recommendations of the manufacture for the appropriate device.

**TECHNOLOGICAL/SUBSTANTIAL EQUIVALENCE SUMMARY:** The technical characteristics for the new device do not differ from those of the currently marketed device. These devices have the same design, the same fundamental scientific and chemical characteristics, the same labeling, and have the same intended use. The differences in the proposed new device are an increase in the size and fill volume of the syringe. All other aspects of the product design remain the same. This device is categorized in ISO 10993-1:2009 as "External communicating device – blood path, indirect per section 5.2.2(a). The device will have limited contact of less than or equal to 24 hours. All materials contact the fluid path and are treated as indirect patient contact. The syringe device is fabricated from the following raw materials:

- Polypropylene homopolymer pellets (PF535)
- Dow Corning 360 Medical fluid
- West Pharmaceutical Rubber Plunger Tips
- Tip Cap Non-sterile Basell PF535 Polypropylene, Alpha Gray TPE G968B 4170

No other materials including plasticizers, additives, crosslink agents, reagents, colorants, inks, adhesives, surfactants, detergents, etc., are used during the manufacture of the syringes. The device does not use an energy source.

### Technological/Substantial Equivalence Comparison Table:

Technological/Substantial Equivalence Table		
	Predicate Device	New Device
<b>Intended Use</b>	Intended use: 0.9% Sodium Chloride Flush Syringes are intended for use in flushing compatible intravenous administration sets and indwelling intravenous access devices.	Intended use: 0.9% Sodium Chloride Flush Syringes are intended for use in flushing compatible intravenous administration sets and indwelling intravenous access devices.
<b>Design</b>	Predicate device and new device have identical design.	New device has the same design as predicate.
<b>Chemical Composition of Barrel</b>	Non-sterile Polypropylene PF-535 Resin	Non-sterile Polypropylene PF-535 Resin
<b>Chemical Composition of Plunger</b>	Non-sterile Black Pharmaceutical Grade Rubber (Not made with Natural Rubber Latex)	Non-sterile Black Pharmaceutical Grade Rubber (Not made with Natural Rubber Latex)
<b>Chemical Composition Tip Cap</b>	Non-sterile Basell PF535 Polypropylene, Alpha Gray TPE G968B 4170	Non-sterile Basell PF535 Polypropylene, Alpha Gray TPE G968B 4170
<b>Environment</b>	Positive Differential Controlled and Monitored	Positive Differential Controlled and Monitored
<b>Energy Source</b>	There is not an energy source. The device is operated mechanically.	There is not an energy source. The device is operated mechanically.
<b>Non-Pyrogenic</b>	Entire device is nonpyrogenic	Entire device is nonpyrogenic
<b>Additives, latex, or preservatives</b>	No additives, natural rubber, or preservatives were used in the manufacture of the syringes.	No additives, natural rubber, or preservatives were used in the manufacture of the syringes.
<b>Sterile Barrier Package</b>	Sterile barrier Pouch polypropylene film 3-6 mil	Sterile barrier Pouch polypropylene film 3-6 mil
<b>Sterility Assurance Level</b>	10 <sup>-6</sup>	10 <sup>-6</sup>
<b>Sterility Labeling of Device</b>	Fluid path and outside of device are sterile.	Fluid path and outside of device are sterile.
<b>Sterilization Method</b>	Gamma	Gamma
<b>Expiry Dating</b>	2 years	2 years
<b>Filling Process</b>	The filling process occurs in a positive differential, monitored, and controlled environment. The solution is contained in a sterile closed system.	The filling process occurs in a positive differential, monitored, and controlled environment. The solution is contained in a sterile closed system.
<b>Equivalent Bench and Stability Testing</b>	The predicate device Bench and Stability tests included: <ul style="list-style-type: none"> <li>• Sterility</li> <li>• Pyrogen (LAL) analysis <ul style="list-style-type: none"> <li>• pH</li> </ul> </li> <li>• Water Loss</li> <li>• Iron</li> <li>• Heavy Metals</li> <li>• Sodium, Chloride</li> <li>• Particulate Matter</li> </ul>	The same Bench and Stability tests were performed on the new device as the predicate device. Bench and Stability tests included: <ul style="list-style-type: none"> <li>• Sterility</li> <li>• Pyrogen (LAL) analysis <ul style="list-style-type: none"> <li>• pH</li> </ul> </li> <li>• Water Loss</li> <li>• Iron</li> <li>• Heavy Metals</li> <li>• Sodium, Chloride</li> <li>• Particulate Matter</li> </ul>
<b>Size and Fill Volumes</b>	3 mL/12 mL; 5 mL/12mL, 10 mL/12mL	20 mL/20 mL

**Conclusion:** The new device is identical to the predicate device in plastic materials composition, the form, and function (e.g. Flushing of vascular access devices). The two changes to the new device involve 1. Increase in syringe size from a 12 mL syringe to a 20 mL syringe and 2. Increase in the solution volume. Non-clinical verification testing for the proposed change involved chemical-physical, functional, and product stability testing. The results of testing conducted verify the new device performed in an equivalent manner to the predicate device. Therefore, the new device is substantially equivalent to the predicate device. Other companies have FDA 510(k) clearance for similar devices.